Why Shares of Zalicus May Be Ready To Make A Move Print E-mail
By Michael Morhamus, Contributor   
Wednesday, 06 November 2013 06:21
icon_MarketCatalystIn case you haven't already heard, over in the

Error. Page cannot be displayed. Please contact your service provider for more details. (30)

biotech sector many investors are on the edge of their seats waiting for a potentially huge binary event from Zalicus, Inc. (NASDAQ:ZLCS);
FDA Rescinds SPA for Amarin’s Vascepa, Now What? Print E-mail
By Brian Wilson-Lead Contributor   
Thursday, 31 October 2013 07:56
Yesterday, the beaten down small pharmaceutical company Amarin (NASDAQ: AMRN) received word that the FDA had rescinded the Special Protocol Assessment (SPA) declaration that was originally given to Vascepa for the ANCHOR indication.
3 Biotech Catalysts to Hit Before 2014 Print E-mail
By Brian Wilson - Lead Contributor   
Wednesday, 30 October 2013 09:01
We’re about to start November 2013, and we’re wrapping up what should be an exceptionally good year for the biotech sector and the stock market as a whole.
Recent FDA Headlines Call Attention To Compelling Zalicus Trade Print E-mail
By David Ibrahim of MarketScanners   
Tuesday, 29 October 2013 05:45
icon_bottombouncerOur Seeking Alpha followers know that one of our favorite times to buy and trade stocks is when they may have hit technical and fundamental bottoms.
Categorizing Biology Investments, and 2 Niche Market Stock Picks Print E-mail
By Brian Wilson-Lead Contributor   
Monday, 28 October 2013 07:48
Note: In addition to my regular discussion on select companies in the life science (“applied biology”) space, I’ve included a top-down discussion and exemplification of my main categorization method.
Cytokinetics Continues Sliding on Sector Weakness Print E-mail
By Brian Wilson-Lead Contributor   
Thursday, 24 October 2013 08:47
Last week, we expressed our opinion that the biotech sector was becoming quite expensive, and that investors might want to use more caution with some of the companies that have seen extreme outperformance since the start of the year.
Big Expected Move in Aegerion Pharma from Q3 Earnings Print E-mail
By Brian Wilson-Lead Contributor   
Wednesday, 23 October 2013 08:11
In anticipation of an earnings release next week, implied volatility (IV) has increased quite significantly for Aegerion Pharmaceuticals (NASDAQ: AEGR).
DECN Set To Climb As GenStrip Enters Blood Glucose Monitoring Market With First Shipments Print E-mail
By Staff and Wire Reports   
Tuesday, 22 October 2013 08:44
Icon_alert_keyOn October 1, 2013 Decision Diagnostics Corporation (OTCBB: DECN) announced in a press release that they have scheduled bulk shipments of their first proprietary product, the Shasta GenStrip™ glucose test strip that is compatible with Johnson & Johnson’s Lifescan Ultra glucose monitoring devices. 
Ariad - The Other “Biotech Blowup” of October 2013 Print E-mail
By Brian Wilson-Lead Contributor   
Monday, 21 October 2013 08:57
Amarin was not the only high-profile biotech “blowup” in recent history. Investors who were watching Ariad Pharmaceuticals (NASDAQ: ARIA) saw an even more traumatic selloff throughout the month.
Sunshine Heart’s C Pulse Device Could Be Life Changer For Heart Failure Patients Print E-mail
By Scott Matusow   
Monday, 21 October 2013 08:55
Recent developments in the medical device industry have paved the way for some strong achievements in many different sectors of the health care industry.
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 18 of 55


BioMedReports F.D.A. names and
shames drug makers to encourage generic competition https://t.co/pLdi3Yd8PR https://t.co/pLdi3Yd8PR
BioMedReports Trump’s lawyer pitched himself as a fixer to #Novartis and got paid $1.2 million https://t.co/8JKXtruRLL https://t.co/8JKXtruRLL
BioMedReports Judge Rules Biogen Must Face Federal Portion of FCA Complaint... https://t.co/WJL7BWxvOV